RT Journal
A1 Braillon A
T1 EXperience is a gloomy lantern that does not even illuminate its bearer
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD February 13
VO 172
IS 3
SP 294
OP 294
DO 10.1001/archinternmed.2011.760
UL http://dx.doi.org/10.1001/archinternmed.2011.760
AB 
Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions.